S. Nabavi, Mehrnoosh Mehrabani, L. Ghalichi, M. Nahayati, Mehran Ghaffari, F. Ashtari, S. E. Mohammadianinejad, S. Karimi, M. Salari, L. Faghani, S. Yazdanbakhsh, Abbas Najafian, M. Vosough
{"title":"BBIBP-CorV(国药)COVID-19疫苗在多发性硬化症患者中的安全性:来自伊朗的报告","authors":"S. Nabavi, Mehrnoosh Mehrabani, L. Ghalichi, M. Nahayati, Mehran Ghaffari, F. Ashtari, S. E. Mohammadianinejad, S. Karimi, M. Salari, L. Faghani, S. Yazdanbakhsh, Abbas Najafian, M. Vosough","doi":"10.14302/issn.2690-4837.ijip-22-4342","DOIUrl":null,"url":null,"abstract":"Introduction: Vaccination against SARS CoV-2 started on March 2020 in Iran and people with multiple sclerosis (pwMS) have a priority to be vaccinated in line of other high-risk population. Up to now, BBIBP-CorV (Sinopharm) is the main vaccine which have been used in Iranian population, and in high risk population such as pwMS. \nMethod: In this survey, the safety and possible side effects of this vaccine after the first or/and second doses in 520 pwMS have been assessed from July to August 2021. MS Patients who have received one or two doses of Sinopharm vaccine were evaluated.\nResults: Around 44% of pwMS who received Sinopharm reported few minor side effects, whereas its side effect have been reported in 60% of patients who received the second dose. All side effects have begun within the first 24 hours and subsided between 48-96 hours afterward. No serious side effects or mortality have been reported. There was no correlation between the side effects and age, the disability status, and the type of first or second line DMDs (disease modifying drugs). Only some side effects were significantly higher in the progressive form of the disease. \nConclusion: MS patients can receive Sinopharm vaccine safely and the minor side effects should not scare them.\n\nKeywords: Sinopharm BBIBP-CorV, multiple sclerosis, disease modifying drugs, safety","PeriodicalId":325366,"journal":{"name":"International Journal of Infection Prevention","volume":"27 10 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety Of BBIBP-CorV (Sinopharm) COVID-19 Vaccination In People With Multiple Sclerosis: A Report From Iran\",\"authors\":\"S. Nabavi, Mehrnoosh Mehrabani, L. Ghalichi, M. Nahayati, Mehran Ghaffari, F. Ashtari, S. E. Mohammadianinejad, S. Karimi, M. Salari, L. Faghani, S. Yazdanbakhsh, Abbas Najafian, M. Vosough\",\"doi\":\"10.14302/issn.2690-4837.ijip-22-4342\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Vaccination against SARS CoV-2 started on March 2020 in Iran and people with multiple sclerosis (pwMS) have a priority to be vaccinated in line of other high-risk population. Up to now, BBIBP-CorV (Sinopharm) is the main vaccine which have been used in Iranian population, and in high risk population such as pwMS. \\nMethod: In this survey, the safety and possible side effects of this vaccine after the first or/and second doses in 520 pwMS have been assessed from July to August 2021. MS Patients who have received one or two doses of Sinopharm vaccine were evaluated.\\nResults: Around 44% of pwMS who received Sinopharm reported few minor side effects, whereas its side effect have been reported in 60% of patients who received the second dose. All side effects have begun within the first 24 hours and subsided between 48-96 hours afterward. No serious side effects or mortality have been reported. There was no correlation between the side effects and age, the disability status, and the type of first or second line DMDs (disease modifying drugs). Only some side effects were significantly higher in the progressive form of the disease. \\nConclusion: MS patients can receive Sinopharm vaccine safely and the minor side effects should not scare them.\\n\\nKeywords: Sinopharm BBIBP-CorV, multiple sclerosis, disease modifying drugs, safety\",\"PeriodicalId\":325366,\"journal\":{\"name\":\"International Journal of Infection Prevention\",\"volume\":\"27 10 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Infection Prevention\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14302/issn.2690-4837.ijip-22-4342\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infection Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14302/issn.2690-4837.ijip-22-4342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Safety Of BBIBP-CorV (Sinopharm) COVID-19 Vaccination In People With Multiple Sclerosis: A Report From Iran
Introduction: Vaccination against SARS CoV-2 started on March 2020 in Iran and people with multiple sclerosis (pwMS) have a priority to be vaccinated in line of other high-risk population. Up to now, BBIBP-CorV (Sinopharm) is the main vaccine which have been used in Iranian population, and in high risk population such as pwMS.
Method: In this survey, the safety and possible side effects of this vaccine after the first or/and second doses in 520 pwMS have been assessed from July to August 2021. MS Patients who have received one or two doses of Sinopharm vaccine were evaluated.
Results: Around 44% of pwMS who received Sinopharm reported few minor side effects, whereas its side effect have been reported in 60% of patients who received the second dose. All side effects have begun within the first 24 hours and subsided between 48-96 hours afterward. No serious side effects or mortality have been reported. There was no correlation between the side effects and age, the disability status, and the type of first or second line DMDs (disease modifying drugs). Only some side effects were significantly higher in the progressive form of the disease.
Conclusion: MS patients can receive Sinopharm vaccine safely and the minor side effects should not scare them.
Keywords: Sinopharm BBIBP-CorV, multiple sclerosis, disease modifying drugs, safety